Ultragenyx Says Week 96 Phase 3 Data On GENGLYCOS In Glycogen Storage Disease Type Ia Show 61% Mean Reduction In Daily Cornstarch Intake, With 33% Of Treatment Group And 42% Of Crossover Group Eliminating Nighttime Dosing
Share
Why It Matters
Ultragenyx tested a medicine that helps people with a rare disease need way less special starch to stay healthy—some patients didn't even need it at night anymore. When a company's medicine works really well in testing, it shows the company might have something valuable to sell, which is important information to notice.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.